Advertisement
Advertisement

SPRB

SPRB logo

Spruce Biosciences, Inc. Common Stock

51.87
USD
Sponsored
-0.27
-0.52%
Jun 24, 16:00 UTC -4
Closed
exchange

After-Market

51.16

-0.70
-1.36%

SPRB Earnings Reports

Positive Surprise Ratio

SPRB beat 15 of 23 last estimates.

65%

Next Report

Date of Next Report
Aug 12, 2026
Estimate for Q2 26 (Revenue/ EPS)
--
/
-$6.23
Implied change from Q1 26 (Revenue/ EPS)
--
/
-30.31%
Implied change from Q2 25 (Revenue/ EPS)
--
/
+78.00%

Spruce Biosciences, Inc. Common Stock earnings per share and revenue

On May 13, 2026, SPRB reported earnings of -8.94 USD per share (EPS) for Q1 26, beating the estimate of -8.99 USD, resulting in a 0.58% surprise. Revenue reached --, compared to an expected --, with a 0.00% difference. The market reacted with a -0.05% price change (close before vs. close after earnings).
Looking ahead to Q2 26, 5 analysts forecast an EPS of -6.23 USD, with revenue projected to reach -- USD, implying an decrease of -30.31% EPS, and increase of 0.00% in Revenue from the last quarter.

Industry Peers’ Earnings

Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.

logo
enGene Therapeutics Inc. Common Stock
Report Date
Jun 15, 2026 For Q2 26
Estimate
-$0.47
Actual
-$0.43
Surprise
+10.32%
logo
Prenetics Global Limited Class A Ordinary Share
Report Date
Jun 10, 2026 For Q1 26
Estimate
-$1.10
Actual
-$1.61
Surprise
-45.36%
logo
Anixa Biosciences, Inc.
Report Date
Jun 10, 2026 For Q2 26
Estimate
-$0.08
Actual
-$0.07
Surprise
+21.61%
logo
Vistagen Therapeutics, Inc. Common Stock
Report Date
Jun 15, 2026 For Q4 26
Estimate
-$0.34
Actual
-$0.37
Surprise
-7.75%
FAQ
For Q1 2026, Spruce Biosciences, Inc. Common Stock reported EPS of -$8.94, beating estimates by 0.58%, and revenue of $0.00, 0% as expectations.
The stock price moved down -0.05%, changed from $59.37 before the earnings release to $59.34 the day after.
The next earning report is scheduled for Aug 12, 2026.
Based on 5 analysts, Spruce Biosciences, Inc. Common Stock is expected to report EPS of -$6.23 and revenue of -- for Q2 2026.
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement